In this Consultant360 interview, Brian Bergmark, MD explains how olezarsen, an RNA-targeted therapy targeting APOC3, may help address residual cardiovascular risk in patients with moderate...
In this Consultant360 interview, Brian Bergmark, MD explains how olezarsen, an RNA-targeted therapy targeting APOC3, may help address residual cardiovascular risk in patients with moderate...
In this Consultant360 interview, Brian Bergmark, MD explains how olezarsen, an RNA-targeted therapy targeting APOC3, may help address residual cardiovascular risk in patients with moderate...
In this Consultant360 interview, Brian Bergmark, MD explains how olezarsen, an RNA-targeted therapy targeting APOC3, may help address residual cardiovascular risk in patients with moderate...
In this Consultant360 interview, Brian Bergmark, MD explains how olezarsen, an RNA-targeted therapy targeting APOC3, may help address residual cardiovascular risk in patients with moderate...
In this Consultant360 interview, Brian Bergmark, MD explains how olezarsen, an RNA-targeted therapy targeting APOC3, may help address residual cardiovascular risk in patients with moderate...
In a recent presentation at Practical Updates in Primary Care, Joel M. Gelfand, MD, provided an overview of psoriasis care for primary care providers alongside co-presenter Annie Truss, MD. In this...
In a recent presentation at Practical Updates in Primary Care, Joel M. Gelfand, MD, provided an overview of psoriasis care for primary care providers alongside co-presenter Annie Truss, MD. In this...
In a recent presentation at Practical Updates in Primary Care, Joel M. Gelfand, MD, provided an overview of psoriasis care for primary care providers alongside co-presenter Annie Truss, MD. In this...
Veteran dermatology Physician Assistant Douglas DiRuggiero, PA-C, DMSc, shares practical insights on how he incorporates ZORYVE® (roflumilast) into the treatment of atopic dermatitis, seborrheic...
